API | omarigliptin

omarigliptin Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW

Omarigliptin (MK-3102) is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & Co. It inhibits DPP-4 to increase incretin levels, which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying and decreases blood glucose levels. ^Wikipedia

Chemistry

SMILES: CS(=O)(=O)n1cc2CN(Cc2n1)[C@H]3CO[C@@H]([C@@H](N)C3)c4cc(F)ccc4F
InChIKey: MKMPWKUAHLTIBJ-ISTRZQFTSA-N
Mol. Mass: 398.44
ALogP: 1.14 Partition coefficient
ChEMBL Molecule:
omarigliptin

More Chemistry

Pharmacology

Mechanism of Action:
- Dipeptidyl peptidase 4 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

2-(2,5-difluorophenyl)-5-(2-(methylsulfonyl)-2,6-dihydropyrrolo(3,4-c)pyrazol-5(4h)-yl)tetrahydro-2h-pyran-3-amine | marizev | mk3102 | mk-3102 | omarigliptin

Organizations (6)

Research & Development (6)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (1)

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (4)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 4)

Glucose Intolerance (Phase 2)

Renal Insufficiency, Chronic (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 22
# of Trial Organizations: 6

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue